Literature DB >> 15138190

Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers.

Alyson J Littman1, Lisa A Jackson, Emily White, Mark D Thornquist, Charlotte A Gaydos, Thomas L Vaughan.   

Abstract

To evaluate the reliability of Chlamydia pneumoniae-specific immunoglobulin G (IgG) and IgA antibody titers as measured by the microimmunofluorescence (MIF) test, we compared results from 392 individuals using a standard MIF protocol at two academic laboratories. The kappas for dichotomous titers (>/=16 versus <16) were 0.39 for IgA and 0.53 for IgG. Measurement error likely attenuates C. pneumoniae-disease associations; the magnitude of attenuation can be estimated from results of studies such as this one.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15138190      PMCID： PMC404569          DOI： 10.1128/CDLI.11.3.615-617.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  10 in total

1.  Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.

Authors:  T O Messmer; J Martinez; F Hassouna; E R Zell; W Harris; S Dowell; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.

Authors:  R W Peeling; S P Wang; J T Grayston; F Blasi; J Boman; A Clad; H Freidank; C A Gaydos; J Gnarpe; T Hagiwara; R B Jones; J Orfila; K Persson; M Puolakkainen; P Saikku; J Schachter
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

Review 3.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

Authors:  S F Dowell; R W Peeling; J Boman; G M Carlone; B S Fields; J Guarner; M R Hammerschlag; L A Jackson; C C Kuo; M Maass; T O Messmer; D F Talkington; M L Tondella; S R Zaki
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

4.  Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis.

Authors:  J Danesh; P Whincup; S Lewington; M Walker; L Lennon; A Thomson; Y-K Wong; X Zhou; M Ward
Journal:  Eur Heart J       Date:  2002-03       Impact factor: 29.983

5.  The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation.

Authors:  S p Wang
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

6.  Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; Y Wong; M Bernardes-Silva; M Ward
Journal:  BMJ       Date:  2000-07-22

7.  Misclassification of a prognostic dichotomous variable: sample size and parameter estimate adjustment.

Authors:  C J Tavaré; E L Sobel; F H Gilles
Journal:  Stat Med       Date:  1995-06-30       Impact factor: 2.373

8.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

9.  Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET).

Authors:  M D Thornquist; G S Omenn; G E Goodman; J E Grizzle; L Rosenstock; S Barnhart; G L Anderson; S Hammar; J Balmes; M Cherniack
Journal:  Control Clin Trials       Date:  1993-08

10.  Performance of three microimmunofluorescence assays for detection of Chlamydia pneumoniae immunoglobulin M, G, and A antibodies.

Authors:  Mette Bennedsen; Lene Berthelsen; Inga Lind
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
  10 in total
  6 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders.

Authors:  Carlo Contini; Silva Seraceni; Rosario Cultrera; Massimiliano Castellazzi; Enrico Granieri; Enrico Fainardi
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-21

4.  Risk factors for the development of acute lung injury in patients with infectious pneumonia.

Authors:  Marija Kojicic; Guangxi Li; Andrew C Hanson; Kun-Moo Lee; Lokendra Thakur; Jayanth Vedre; Adil Ahmed; Larry M Baddour; Jay H Ryu; Ognjen Gajic
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

Review 5.  Diagnostic test for etiologic agents of community-acquired pneumonia.

Authors:  John G Bartlett
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

6.  Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.

Authors:  Xin Xu; Zhiqiang Liu; Weimin Xiong; Minglian Qiu; Shuling Kang; Qiuping Xu; Lin Cai; Fei He
Journal:  BMC Cancer       Date:  2020-09-22       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.